NCT00602602View on ClinicalTrials.gov

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Pancreatic Cancer

Interventions

BIOLOGICAL

bevacizumab

DRUG

fluorouracil

DRUG

gemcitabine hydrochloride

DRUG

oxaliplatin

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

PROCEDURE

conventional surgery

PROCEDURE

endoscopic biopsy

PROCEDURE

laparoscopy

RADIATION

radiation therapy

Trial Locations (1)

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00602602 - Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter